Shares of Zoetis Inc. (NYSE:ZTS – Get Free Report) have been given an average rating of “Buy” by the nine analysts that are covering the company, Marketbeat reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have updated their coverage on the stock in the last year is $217.11.
Several equities research analysts have recently weighed in on the company. The Goldman Sachs Group reduced their price target on Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a report on Monday, May 6th. BTIG Research lifted their target price on Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a research report on Monday, August 12th. Piper Sandler upped their price target on shares of Zoetis from $195.00 to $210.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Stifel Nicolaus raised their price target on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, August 5th. Finally, Argus raised shares of Zoetis to a “strong-buy” rating in a research report on Friday, August 9th.
Get Our Latest Research Report on Zoetis
Institutional Investors Weigh In On Zoetis
Zoetis Stock Down 0.7 %
NYSE ZTS opened at $180.96 on Friday. Zoetis has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a market capitalization of $82.57 billion, a price-to-earnings ratio of 34.87, a PEG ratio of 2.81 and a beta of 0.86. The company has a quick ratio of 2.09, a current ratio of 3.45 and a debt-to-equity ratio of 1.32. The company has a fifty day moving average of $178.56 and a two-hundred day moving average of $175.08.
Zoetis (NYSE:ZTS – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The company reported $1.56 EPS for the quarter, beating the consensus estimate of $1.49 by $0.07. Zoetis had a net margin of 26.29% and a return on equity of 50.67%. The company had revenue of $2.36 billion for the quarter, compared to the consensus estimate of $2.31 billion. During the same period in the prior year, the firm posted $1.41 EPS. The firm’s revenue was up 8.3% compared to the same quarter last year. On average, analysts predict that Zoetis will post 5.84 earnings per share for the current year.
Zoetis Company Profile
Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.
Featured Articles
- Five stocks we like better than Zoetis
- With Risk Tolerance, One Size Does Not Fit All
- Lumen: Among Top Performers Last Month, Still Has Warning Signs
- Insider Trading – What You Need to Know
- Baidu’s Strong Quarter Proves a Smart Pick for Michael Burry
- How to Use the MarketBeat Excel Dividend Calculator
- Intuit Beats Q4 Earnings: AI, Dividends, and a Growth Strategy
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.